GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.
Google has agreed to a $135 million settlement to resolve a class-action lawsuit alleging unauthorized data collection by its Android operating system, pending court approval. The deal also mandates clearer user controls and disclosures.
Ripple has obtained a full Electronic Money Institution (EMI) license from Luxembourg's CSSF, granting it passporting rights across the European Union. This marks a significant regulatory milestone following recent UK approval and a period of aggressive fundraising and acquisitions.
The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.
A British Columbia court has given its final approval to Coeur Mining's planned acquisition of New Gold, moving the deal that will create a North American precious metals giant one step closer to its expected H1 2026 closing.
A Dominus and Cheyne Capital partnership wins City of London approval to convert the Grade II-listed Ibex House into a 382-room hotel, slated for a late 2028 opening, complete with a hospitality academy and restored pub.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
Laura Fernandez, a close ally of outgoing populist President Rodrigo Chaves, has been elected Costa Rica's next leader. She pledges to continue his transformative agenda, including constitutional reforms and emergency measures to combat drug violence, signaling a profound shift for the nation.
Costa Ricans cast ballots Sunday in an election defined by soaring narco-violence, with ruling party candidate Laura Fernandez, promising a Bukele-style crackdown, favored to win. The vote signals a potential rightward shift and constitutional showdown in a nation struggling with its transformation into a major drug trafficking hub.
Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.
Despite a robust drug pipeline and steady long-term gains, AstraZeneca's recent share price stagnation has investors questioning its true worth. A deep dive into valuation models suggests the pharmaceutical giant may be trading at a significant discount to its intrinsic value, even as its P/E ratio appears elevated compared to peers.
Coeur Mining's acquisition of New Gold has received final court approval in British Columbia, marking a pivotal step toward creating a larger, diversified precious metals producer. The deal is poised to reshape the competitive landscape for mid-tier gold and silver miners in North America.
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
At its Annual General Meeting, Thyssenkrupp secured shareholder approval for a €0.15 per share dividend and detailed progress on its pivot to a holding structure, even as it navigates a costly 'year of implementation' with restructuring ahead.
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
